Application of donor-derived nucleic acid in renal transplantation and optimization of key techniques

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035433

Enrollment

Unknown

Registered

2020-08-11

Start date

2020-10-15

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplant

Interventions

Gold Standard:Pathological biopsy of the transplanted kidney

Index test:Creatinine,&#32

urine&#32

output,&#32

cellular&#32

free&#32

DNA,&#32

mitochondrial&#32

DNA

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who received kidney transplantation for the first time; 2. Follow up regularly after operation and take medicine as prescribed by the doctor; 3. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Infection, tumor or pregnancy other than BKV; 2. Irregular random visitors.

Design outcomes

Primary

Measure	Time frame
creatinine;urine volume;Human population reactive antibody;Human major histocompatibility antigens;BK virus;renal pathology;	—

Countries

China

Contacts

Public ContactYuan Xiaodong

Renji Hospital affiliated to Shanghai Jiao Tong University Medical College

sduyuanxd@126.com+86 18516266816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026